Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001178913-21-003512
Filing Date
2021-11-12
Accepted
2021-11-12 16:05:01
Documents
13
Period of Report
2021-11-12
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K/A form8k.htm   iXBRL 8-K/A 43095
  Complete submission text file 0001178913-21-003512.txt   228361

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA cmmb-20211112.xsd EX-101.SCH 4701
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE cmmb-20211112_def.xml EX-101.DEF 18329
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE cmmb-20211112_lab.xml EX-101.LAB 28549
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cmmb-20211112_pre.xml EX-101.PRE 20565
6 EXTRACTED XBRL INSTANCE DOCUMENT form8k_htm.xml XML 6625
Mailing Address KIRYAT ATIDIM, BUILDING 7 TEL AVIV L3 6158002
Business Address KIRYAT ATIDIM, BUILDING 7 TEL AVIV L3 6158002 972-77-331-0156
Chemomab Therapeutics Ltd. (Filer) CIK: 0001534248 (see all company filings)

EIN.: 813676773 | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-38807 | Film No.: 211403344
SIC: 2834 Pharmaceutical Preparations